Hyperuricemia exacerbates chronic cyclosporine nephropathy

被引:97
作者
Mazzali, M
Kim, YG
Suga, S
Gordon, KL
Kang, DK
Jefferson, JA
Hughes, J
Kivlighn, SD
Lan, HY
Johnson, RJ
机构
[1] Univ Washington, Med Ctr, Div Nephrol, Seattle, WA 98185 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Nephrol, Seoul, South Korea
[3] Merck & Co Inc, West Point, PA 19486 USA
[4] Univ Hong Kong, Queen Mary Hosp, Div Nephrol, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1097/00007890-200104150-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Hyperuricemia frequently complicates cyclosporine (CSA) therapy. The observation that longstanding hyperuricemia is associated with chronic tubulointerstitial disease and intrarenal vasoconstriction raised the hypothesis that hyperuricemia might contribute to chronic CSA nephropathy. Methods. CSA nephropathy was induced by the administration of CSA (15 mg/kg/day) for 5 and 7 weeks to rats on a low salt diet (CSA group). The effect of hyperuricemia on CSA nephropathy was determined by blocking the hepatic enzyme uricase with oxonic acid (CSA-OA). Control groups included rats treated with vehicle (VEH) and oxonic acid alone (OA). Histological and functional studies were determined at sacrifice. Results. CSA treated rats developed mild hyperuricemia with arteriolar hyalinosis, tubular injury and striped interstitial fibrosis. CSA-OA treated rats had higher uric acid levels in association with more severe arteriolar hyalinosis and tubulointerstitial damage. Intrarenal urate crystal deposition was absent in all groups. Both CSA and CSA-OA treated rats had increased renin and decreased NOS1 and NOS3 in their kidneys, and these changes are more evident in CSA-OA treated rats. Conclusion. An increase in uric acid exacerbates CSA nephropathy in the rat. The mechanism does not involve intrarenal uric acid crystal deposition and appears to involve activation of the renin angiotensin system and inhibition of intrarenal nitric oxide production.
引用
收藏
页码:900 / 905
页数:6
相关论文
共 37 条
  • [11] EVALUATION OF PATHOGENESIS OF GOUTY KIDNEY
    EMMERSON, BT
    ROW, PG
    [J]. KIDNEY INTERNATIONAL, 1975, 8 (02) : 65 - 71
  • [12] RENAL PROLIFERATIVE AND PHENOTYPIC CHANGES IN RATS WITH 2-KIDNEY, ONE-CLIP GOLDBLATT HYPERTENSION
    ENG, E
    VENIANT, M
    FLOEGE, J
    FINGERLE, J
    ALPERS, CE
    MENARD, J
    CLOZEL, JP
    JOHNSON, RJ
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1994, 7 (02) : 177 - 185
  • [13] OSTEOPONTIN EXPRESSION IN ANGIOTENSIN-II-INDUCED TUBULOINTERSTITIAL NEPHRITIS
    GIACHELLI, CM
    PICHLER, R
    LOMBARDI, D
    DENHARDT, DT
    ALPERS, CE
    SCHWARTZ, SM
    JOHNSON, RJ
    [J]. KIDNEY INTERNATIONAL, 1994, 45 (02) : 515 - 524
  • [14] HYPERURICEMIA AFTER RENAL-TRANSPLANTATION
    GORES, PF
    FRYD, DS
    SUTHERLAND, DER
    NAJARIAN, JS
    SIMMONS, RL
    [J]. AMERICAN JOURNAL OF SURGERY, 1988, 156 (05) : 397 - 400
  • [15] A MODIFIED CARBONATE-PHOSPHOTUNGSTATE METHOD FOR THE DETERMINATION OF URIC ACID AND COMPARISON WITH THE SPECTROPHOTOMETRIC URICASE METHOD
    HENRY, RJ
    SOBEL, C
    KIM, J
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1957, 28 (02) : 152 - 160
  • [16] RENAL HANDLING OF URIC-ACID UNDER CYCLOSPORIN-A TREATMENT
    HOYER, PF
    LEE, IJ
    OEMAR, BS
    KROHN, HP
    OFFNER, G
    BRODEHL, J
    [J]. PEDIATRIC NEPHROLOGY, 1988, 2 (01) : 18 - 21
  • [17] Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease
    Johnson, RJ
    Kivlighn, SD
    Kim, YG
    Suga, S
    Fogo, AB
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (02) : 225 - 234
  • [18] KAHL LE, 1989, AM J MED, V87, P289
  • [19] Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children
    Laine, J
    Holmberg, C
    [J]. NEPHRON, 1996, 74 (02): : 318 - 323
  • [20] Salt-sensitive hypertension develops after short-term exposure to angiotensin II
    Lombardi, D
    Gordon, KL
    Polinsky, P
    Suga, S
    Schwartz, SM
    Johnson, RJ
    [J]. HYPERTENSION, 1999, 33 (04) : 1013 - 1019